- Uptravi is used to treat the rare and potentially deadly disease
- J&J seeks court orders blocking copies until the patents have expired, and to collect cash compensation if copies are made before then, according to a
complaint filed Thursday in federal court in Newark, New Jersey - Patents expire in April 2023 and in June and August 2030: FDA Orange Book
- J&J...
J&J’s Actelion, Nippon Sue to Block Copies of Uptravi Lung Drug
April 9, 2020, 10:23 PM